Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H. Luo F, et al. Among authors: chen q. Cell Mol Immunol. 2024 Jan;21(1):60-79. doi: 10.1038/s41423-023-01112-y. Epub 2023 Dec 7. Cell Mol Immunol. 2024. PMID: 38062129 Free PMC article.
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX, Liu FR, Zhang Y, Chen Q, Chen ZQ, Liu QW, Huang Y, Yang YP, Fang WF, Xi N, Kang N, Zhuang YL, Zhang Q, Jiang YZ, Zhang L, Zhao HY. Ma YX, et al. Among authors: chen q, chen zq. Front Immunol. 2022 Oct 20;13:1024755. doi: 10.3389/fimmu.2022.1024755. eCollection 2022. Front Immunol. 2022. PMID: 36341335 Free PMC article. Clinical Trial.
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Ma Y, Chen Q, Zhang Y, Xue J, Liu Q, Zhao Y, Yang Y, Huang Y, Fang W, Hou Z, Li S, Wang J, Zhang L, Zhao H. Ma Y, et al. Among authors: chen q. Cancer Chemother Pharmacol. 2023 Nov;92(5):411-418. doi: 10.1007/s00280-023-04563-2. Epub 2023 Jul 31. Cancer Chemother Pharmacol. 2023. PMID: 37518060
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.
Ma Y, Luo F, Zhang Y, Liu Q, Xue J, Huang Y, Zhao Y, Yang Y, Fang W, Zhou T, Chen G, Cao J, Chen Q, She X, Luo P, Liu G, Zhang L, Zhao H. Ma Y, et al. Among authors: chen q, chen g. Cell Rep Med. 2024 Feb 20;5(2):101414. doi: 10.1016/j.xcrm.2024.101414. Epub 2024 Feb 7. Cell Rep Med. 2024. PMID: 38330942 Free PMC article. Clinical Trial.
34,044 results
You have reached the last available page of results. Please see the User Guide for more information.